Phase I Pharmacokinetic and Pharmacodynamic Study of a New Anthrapyrazole, CI-937 (DUP937)

Charles Erlichman, Malcolm Moore, Ian G. Kerr, Bradley Wong, Elizabeth Eisenhauer, Benny Zee, Lloyd R. Whitfield

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

We performed a phase I trial of CI-937 (DUP937), an anthrapyrazole, with the following objectives: (a) to determine the maximally tolerated dose in humans; (b) to define the toxicity spectrum of this agent; (c) to describe the pharmacokinetics of the drug; to test a pharmacokinetics based hypothesis of dose escalation; and (<â€to¢)relate drug pharmacoki netics to pharmacodynamics. CI-937 was administered as a single bolus injection every 3-4 weeks at doses ranging from 3.6 to 25.2 mg/m2. Thirty-two patients and 57 courses were Ã

Original languageEnglish (US)
Pages (from-to)6317-6322
Number of pages6
JournalCancer research
Volume51
StatePublished - Dec 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I Pharmacokinetic and Pharmacodynamic Study of a New Anthrapyrazole, CI-937 (DUP937)'. Together they form a unique fingerprint.

  • Cite this

    Erlichman, C., Moore, M., Kerr, I. G., Wong, B., Eisenhauer, E., Zee, B., & Whitfield, L. R. (1991). Phase I Pharmacokinetic and Pharmacodynamic Study of a New Anthrapyrazole, CI-937 (DUP937). Cancer research, 51, 6317-6322.